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INTRODUCTION 52
Microbiomes, both in terms of function and diversity, have recently been a topic of considerable 53 interest. The gut microbiome has gotten special attention due to its high complexity and 54 importance to health [1] [2] [3] [4] [5] [6] [7] [8] [9] . So far, studies have almost exclusively focused on species or higher-55 level diversity. However, this paints an incomplete picture, since strains within the same species 56 can be of distinct clonal origin and have vastly different metabolic, pathogenic, and antibiotic 57 resistance profiles [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Importantly, multidrug-resistant bacterial strains have been found 58 competing with commensal strains in the gut, even without antibiotic pressure [18] [19] [20] [21] [22] [23] . Thus, there is 59 a pressing need to identify strains in the human microbiome for species of critical health 60 importance. 61
Escherichia coli is one of the most common residents of the gut. While primarily a commensal 62 colonizer, extra-intestinal pathogenic E. coli clones are implicated in a variety of diseases, 63 4 including urinary tract infections (UTIs) -a leading cause of human antibiotic use [24] [25] [26] [27] [28] . The 64 spread of multi-drug resistant E. coli is now a major health concern, especially the pandemic 65 fimH30 subclone of sequence type ST131 (H30). Though recently-emerged, H30 is now globally 66 distributed and comprises up to half of all urinary and bloodstream isolates of E. coli that are 67 fluoroquinolone-resistant and produce extended-spectrum beta-lactamases (ESBL) [29] [30] [31] [32] [33] . 68
Additionally, it is strongly associated with drug-bug mismatches and adverse outcomes in elderly 69 and immunocompromised individuals [31] [32] [33] [34] . Somewhat paradoxically, H30 is also a persistent gut 70 colonizer of healthy people and frequently causes asymptomatic bacteriuria (ABU) in such 71 carriers 35 . Yet, the relative clonal predominance of H30 strains among E. coli colonizing the gut 72 or bladder in healthy carriers remains unknown. Answering these questions could have a 73 significant impact on understanding the spread of antibiotic resistance and its reservoirs. 74
Currently, microbiome diversity is studied by sequencing the 16S rRNA gene, but this cannot 75 capture clonal diversity 36, 37 . Conventional methods for assessing clonal diversity, such as 76 metagenomic sequencing and single colony typing, are costly and labor intensive. For reliable 77 clonal diversity analysis, metagenomic sequencing requires very high coverage per sample, 78 while single colony typing requires handpicking large numbers of colonies for multi-locus 79 sequence typing (MLST) 38-42. In E. coli, MLST requires assessment of 7 genes per isolate which 80 is analytically complex, costly, labor intensive, and therefore difficult to implement. Previously, 81
we reported an alternative clonotyping method that requires sequencing regions of only 2 genes -82 fumC which is part of the MLST scheme and fimH that encodes a rapidly-evolving fimbrial 83 adhesin 43 . The fumC/fimH-based (CH) typing of E. coli is widely accepted due to its simplicity 84 and ability to not only identify specific STs but subdivide them into smaller subclones 43 . 85 5 Specifically, H30 is identified using the allele combination fumC40/fimH30, while other less 86 resistant ST131 strains have the same fumC but different fimH alleles. 87
Here, we report a high-throughput method for clonal typing of E. coli strains by combining CH 88 typing and deep amplicon sequencing. We developed a new algorithm -Population-Level Allele 89 Profiler (PLAP) -for detecting alleles and predicting the relative prevalence of each allele in a 90 sample. We were able to assess the prevalence of clonal groups (including H30) in multiple fecal 91 and urine samples concurrently, with a limit of relative abundance detection at <1% of the total 92 population. 93
RESULTS 94

Deep amplicon sequencing of defined samples 95
To validate our approach and establish a limit of detection for strain presence, we first tested our 96 deep amplicon sequencing procedure on a set of defined samples. To create the defined samples, 97 we first selected a fecal sample from our lab collection known to contain H30 and ST101. Next, 98
we isolated a single colony from each and confirmed them to be strains of H30 (fumC40/fimH30) 99 and ST101 (fumC41/fimH86) using CH typing. From these single colonies, we first created H30-100 only and ST101-only mixtures of fumC and fimH amplicons. We also created four ST101/H30 101 mixed samples by combining the fumC and fimH amplicons from ST101 and H30 in ST101:H30 102 ratios of 1:1, 1:4, 1:100, and 1:1000. 103
Analysis of raw sequencing data from H30-only and ST101-only samples showed the average 104 coverage of erroneous bases was 0.08% ± 0.09% for both strains. Erroneous bases were observed 105 in both genes across most nucleotide positions. The highest coverage for an erroneous base was 106 0.66% of aligned reads in fumC and 0.45% in fimH for H30, and 0.68% in fumC and 0.46% of 107 6 reads in fimH for ST101. The frequency distribution for erroneous base coverage is presented in 108 Supplemental Figure 1 . 109 Analysis of raw sequencing data from ST101/H30 mixes showed that both H30 and ST101 110 alleles were detectable in the 1:1, 1:4, and 1:100 mixes. In the 1:1000 mix, only alleles of the 111 dominant H30 strain were observed. In the 1:1, 1:4, and 1:100 mixes, input and observed allele 112 prevalence was highly correlated for both fumC and fimH (R 2 =0.996 and 0.997 respectively, 113
Suppl. Fig. 2 ). Erroneous bases were observed at 0.09% ± 0.1% and 0.08% ± 0.09% of aligned 114 reads in fumC and fimH, respectively (Suppl. Fig. 1 ). The highest coverage for erroneous bases 115 among all mixes was 0.79% of aligned reads for fumC and 0.57% of aligned reads for fimH. 116
Since 0.79% of aligned reads was the highest coverage for an erroneous base, we established 117 0.8% as a cutoff for correct base calling in both genes. This cutoff was used for all further PLAP 118 analysis. 119
Deep sequencing of study samples and allele prediction 120
Next, we applied PLAP to 67 participant samples (43 fecal and 24 urine) collected from a 121 previous study 35 . A total of 128 fumC and 129 fimH alleles were predicted across all samples, of 122 which 123 (96.1%) and 125 (96.9%) were previously known fumC and fimH alleles, 123 respectively. 5 novel fumC and 4 novel fimH alleles were potentially detected. All novel fumC 124 and fimH alleles were phylogenetically distant from other alleles predicted in the sample, 125
indicating that these alleles are not artifacts of sequencing (Suppl. Fig. 3, 4 ). These novel alleles 126 nonetheless clustered with other E. coli fumC and fimH alleles, indicating that these are novel E. 127 coli alleles rather than alleles belonging to other species.
7
The average number of alleles predicted per sample was 1.91 ± 0.96 for fumC and 1.93 ± 1.01 129 for fimH. 43 samples had same numbers of predicted fumC and fimH alleles; 24 samples had 130 different numbers of predicted fumC and fimH alleles ( Fig. 1) . Overall, the number of predicted 131 fumC alleles correlated to the number of predicted fimH alleles with an R 2 of 0.88 ( Fig. 1) . 132
To assess the performance of PLAP for predicting alleles, we used samples containing criterion 133 clones -strains previously identified by single colony typing. PLAP detected criterion fimH and 134 fumC alleles in 52 of these samples (90%). In the 6 samples where criterion allele(s) were not 135 found, the criterion clones were ciprofloxacin-resistant, but their isolation from the sample 136 required ≥2 plating attempts. This leads us to believe that these alleles were not detected because 137 they were absent in the MacConkey-plated population prior to deep sequencing. 138 A total of 72 non-criterion (previously unidentified) fumC and 71 non-criterion fimH alleles were 139 predicted by PLAP across all 67 samples. To assess the performance of PLAP on non-criterion 140 alleles, we analyzed 14 samples (10 fecal, 4 urine) predicted to contain 22 non-criterion fumC 141 and 22 non-criterion fimH alleles. 12 of these samples had at least one non-criterion allele 142 alongside criterion alleles; the remaining 2 had multiple non-criterion alleles in each gene only. 143
For each sample ≥40 single colonies were isolated and CH type determined using 7-SNP qPCR, 144 with each CH type verified by sequencing. With these data, we confirmed 19 (86%) predicted 145 non-criterion alleles for each gene. This included one predicted novel fumC allele. Of the 146 unconfirmed alleles, one was not distinguishable by 7-SNP qPCR and had a predicted prevalence 147 of 1%; therefore, we did not attempt to locate it. The remaining unconfirmed alleles had 148 predicted prevalences of <3% and therefore may have been missed due to insufficient sampling. 149
Additionally, all criterion alleles in these samples, 12 per gene, were predicted by PLAP. 150
Prediction of allele prevalence in multi-allele samples 151 8
We have also designed PLAP to predict the within-sample prevalence of each allele. The average 152 allele prevalence in fecal samples was 47.3% ± 4.3% SEM (range 0.88 -100%) for fumC and 153 48.4% ± 4.22% SEM (range 1 -100%) in fimH. The average allele prevalence in urine samples 154 was 64.8% ± 6.91% SEM (range 1.4 -100%) for fumC and 58.3% ± 7.18% SEM (range 1 -155 100%) in fimH. 156
In order to verify that the prevalences predicted by PLAP were accurate, we compared 157 predictions to actual in-sample prevalence using two different methods. 158
In the first method, we used H30 since ascertaining its prevalence is relatively simple. By plating 159 the sample on MacConkey agar then patching onto LB-ciprofloxacin, it is possible to compare 160 the number of cipro-resistant (H30) colonies to the total number of E. coli colonies. The ratio of 161 these two numbers provides the H30 load in a sample. We compared the predicted prevalences of 162 fumC40 and fimH30 to the H30 load in 17 fecal samples containing cipro-resistant H30. 163
Correlations between the H30 load and the predicted prevalence of fumC40 and fimH30 were 164 0.86 and 0.84 respectively (Fig. 2) , indicating that prevalences given by PLAP were 165 representative of actual allele prevalences. To determine whether outliers were present, we 166 calculated the 99% CI range for every sample (see Methods). Three outlier samples were 167 identified (open circles, Fig. 2 ). Since it is possible that these outliers contain ciprofloxacin-168 sensitive non-H30 fimH30-containing clones, fumC-null or fimH-null clones, and/or 169 ciprofloxacin-sensitive H30, we decided to employ screening of a large number of single 170
colonies. 171
In this second method, we used single colony typing for the in-depth characterization of 14 172 multi-allele samples described above, alongside 4 additional single-allele samples (2 fecal, 2 173 urine) for which only one allele per gene was predicted. This set of 18 samples included 11 of 9 the 17 fecal samples used for the H30-based analysis above, including one of the outlier samples. 175
For all 18 samples, we used CH typing of ≥40 single colonies per sample to determine the 176 prevalence of each fumC and fimH allele. Correlation between the PLAP-predicted prevalence 177 and the experimental allele prevalence was 0.98 for both fumC and fimH alleles ( Fig. 3) . As in 178 the H30 analysis above, we determined whether outliers were present using the 99% CI range for 179 every sample. Only one outlier was detected, corresponding to the only sample that contained 180 colonies from which fimH could not be amplified (fimH-null colonies). Furthermore, the sample 181 that was an outlier in the H30-based analysis was found to contain a relatively rare ciprofloxacin-182 sensitive H30. 183
Matching fumC and fimH alleles to predict sample strain content 184
In CH typing, unique combinations of fumC and fimH alleles are used to determine the identities 185 of strains in a sample. Since a strain contains one copy of fumC and fimH, the prevalences of 186 alleles of these two genes in the sequencing data should be identical. For example, in a sample 187 containing 30% H30 (fumC40/fimH30) and 70% ST101 (fumC41/fimH86), we expect to see 30% 188
of fumC reads to be fumC40 and 30% of fimH reads to be fumH30. In reality, however, the 189 prevalences will be slightly different due to PCR and sequencing errors. To establish an 190 acceptable difference between the prevalences of same-strain fumC and fimH alleles, we looked 191 at 11 samples containing unique CH types (i.e. without allele sharing). In these 11 samples, the 192 predicted prevalences of fumC and fimH were highly correlated (0.99, Fig. 3 ). First, we 193 calculated the absolute difference between the predicted fumC and fimH prevalence for each 194 matched pair of alleles. Next, each absolute difference was divided by the predicted fumC or 195 fimH prevalence to obtain a relative deviation ( Fig. 4 ). Finally, we used the relative deviations to 10 derive an equation for the maximum acceptable difference between matching fumC and fimH 197 alleles ( Fig. 4) . 198
While some samples, like those discussed above, contain only unique CH types, others contain 199 CH types with shared alleles. For example, in a sample containing 30% H30 and 70% ST131, 200 which share fumC40, the prevalence of fumC40 is not representative of either H30 or ST131 201 prevalence. For such samples, the minority rule was applied to resolve the strain content. Thus, 202 under the minority rule, the percentage of H30 in the example above would be determined by 203 fimH30, rather than fumC40, since the fimH30 prevalence is smaller. We tested this approach on 204 both the H30 and the 18-sample analysis described above to see if this resolved outliers. In both 205 cases, using the minority rule removed outliers and improved the correlation between predicted 206 and experimental prevalence (Suppl. Fig. 5 ). Thus, we were able to assign strain content and 207 strain prevalence in all samples, including samples with allele sharing. 208
Predicted strain diversity of fecal and urine samples 209
Using the equation described above, we were able to classify all samples in our study into 4 210 categories (see Fig. 5 Overall, 107 fecal and 48 urine strains were predicted, corresponding to 68 clones in fecal 217 samples and 33 clones in urine samples. Of these clones, 50 (73.5%) and 24 (73%) were found in 218 Enterobase, respectively. 219
Out of the 155 total strains predicted, 6 were fumC-null (3.9%) and 2 were fimH-null (1.3%). 220 This is congruent with the occurrence of null alleles in our 18-sample subset, where 1 (3%) out 221 of 35 total strains predicted was a null-allele strain. 222
The average number of strains per sample was 2.47 ± 1.32 for fecal samples and 1. Novel clones 229 17 fecal samples (40%) and 8 urine samples (33%) in our study were found to contain at least 230 one novel CH type. This included 19 fecal and 9 urine CH types not found in Enterobase. Of 231 these, 5 fecal and 3 urine CH types included at least one novel allele, and 14 fecal and 6 urine 232 CH types were combinations of fumC and fimH that were not previously observed (novel CH 233 combinations). Both CH types involving novel alleles and novel CH combinations were 234 observed to be primarily low-frequency clones. The average predicted prevalence for novel CH 235 combinations was 8.7% ± 3.5% SEM (range 1-64.2%), and 13 out of 20 novel CH combinations 236 had predicted prevalences of <5%. One such combination was confirmed in our 14 characterized 237 sample set, consisting of fumC24 and fimH9, with a predicted prevalence of 1.6% and 238 experimental prevalence of 1.2%. 239 Similarly, 7 out of 8 novel allele-containing CH types had predicted prevalences of <2%. The 240 remaining CH type had a predicted prevalence of 70.7% and was detected using single colony 241 typing. The novel fumC allele was paired with fimH47 and was verified to be 8 SNPs away from 242 the closest known allele. The remaining MLST gene alleles for this strain were adk46, icd260, 243 mdh160, gyrB266, purA1, and recA221. 244
Clones below error threshold 245
To ascertain if we could identify alleles at prevalences below our defined error threshold of 246 0.8%, we ran PLAP on the set of 14 multi-allele samples using an error threshold of 0.5%. In 8 247 and 6 samples, respectively, prevalence of fumC and fimH alleles was <0.8%. None of the alleles 248 corresponded to known fumC or fimH alleles. These apparent novel alleles clustered alongside 249 known alleles identified in the sample (Suppl. Fig. 6, 7) , leading us to conclude that these arose 250 due to sequencing or amplification error rather than belonging to clonally different strains. 251
Predicted strain diversity in urine and fecal samples 252
Strain diversity in first fecal samples was comparable with diversity in second fecal samples 253 (paired t-test, p>0.1). Distinguishing between H30-containing and non-H30 samples showed that 254 there was no statistical difference in strain diversity between H30-containing and non-H30 fecal 255 samples of either kind (unpaired t-test, p>0.1), and that there was no difference in diversity 256 between first and second fecal samples in either non-H30 or H30-containing samples (Fig. 6,  257 paired t-test, p>0.1). Both H30 and non-H30 urine samples were less diverse than corresponding 258 13 fecal samples (paired t-test, p<0.01 and 0.02, respectively). However, H30 urine samples were 259 less diverse than non-H30 urine samples (t-test, p=0.04). 260
It is also noteworthy that in 6 out of 23 H30-containing fecal samples, H30 was the only strain 261 predicted, indicating that it may be fully dominant in the gut niche in these participants. 262
Strain turnover in fecal samples 263
There was no correlation between number of strains in the first and second fecal sample, as well 264 as no correlation between number of strains in the urine sample and either fecal sample (Fig. 7) . 265
When comparing the strain content of first and second fecal samples, we found that 92% of non-266 criterion strains appeared to be transient i.e. were detected in one of the fecal samples only. 267
Transient non-criterion strains were also skewed towards lower-frequency strains (t-test, 268 p<0.001, Fig. 8B ). It is possible that these strains are present in both fecal samples but are below 269 our limit of detection in one. However, we find that in one participant (P2, Suppl. Data) the first 270 fecal sample contains 3 ciprofloxacin-sensitive non-criterion strains while the second fecal 271 sample contains only ciprofloxacin-resistant H30 as verified by single colony testing. This leads 272 us to believe that there may be significant strain turnover in our fecal samples overall. 273
DISCUSSION 274
We combined conventional fumC/fimH typing with deep amplicon sequencing to assess E. coli 275 clonal diversity in a high-throughput manner. Our method has several advantages over existing 276 give H30 an advantage is unclear, though previous studies have speculated that some virulence 292 factors may be beneficial for E. coli gut survival 49 . Additionally, our study involved a small 293 number of participants in which H30 was present in the gut and bladder. Therefore, it is possible 294 that host differences play a significant role. Another novel observation was that H30 was the sole 295 detected urinary strain more frequently than other clones, regardless of H30 gut dominance/non-296 dominance. This may indicate that H30 might be an especially well-adapted uropathogen, 297 potentially explaining its association with UTI. Since it is unknown how ABU converts to UTI, 298 further study into H30 dominance in both ABU and UTI are needed. 299
We also uncovered substantial diversity in our samples. This includes significant E. coli diversity 300 in non-H30 urine samples from healthy women. Reports of multi-strain bacteriuria are rare, 301 likely due to the convention of selecting one isolate per urine sample 46, 47 . Therefore, it is 302 unknown how common multi-strain bacteriuria may truly be. Remarkably, we also detected low-303 15 prevalence strains in the gut, some of which were novel clones, with up to 6 clones in a single 304 sample. Gut E. coli diversity of this magnitude is supported by studies typing >200 single 305 colonies per sample 42 . Studies using smaller counts usually report fewer clones, indicating that 306 there may be undescribed E. coli diversity when manageable numbers of colonies are used 44, 45 . 307 Therefore, we believe that microbiome-like approaches to E. coli diversity are necessary to fully 308 understand intra-species dynamics in both the gut and bladder. 309
Our approach does have limitations. Firstly, our lowest detectable strain prevalence is 0.8% of 310 the E. coli population. This limit may be addressed in several ways including use of a high-311
fidelity polymerase and preferential selection of E. coli colonies. However, we also recognize 312 that detection of rare strains may still prove difficult and that methods like ours may not fully 313 replace current techniques. Secondly, our method relies on sub-culturing E. coli. We are aware 314 that, theoretically, some strains could be suppressed during growth on selective media, forming 315 no/smaller colonies and skewing prevalence results. However, we did not encounter this during 316 our study. While amplification of fumC and fimH may be applied to urine samples without 317 culturing, attempts at doing this directly from fecal samples were unsuccessful, possibly due to 318 E. coli comprising <1% of the gut microbiome, making E. coli DNA too rare to effectively 319 amplify. Therefore, we used culturing for all samples. These issues lower the reliability of our 320 approach, but we believe that it remains an important step towards development of 321 comprehensive clonal diversity (clonobiome) assessment tools for any species of interest. 322
MATERIALS AND METHODS 323
Study design and sample processing 324 16 We selected a subset of participants from a previous study carried out by Kaiser Permanente 325 Washington and University of Washington (Seattle, WA) 35 . That study identified healthy gut 326 carriers of ciprofloxacin-resistant E. coli, including E. coli H30. These E. coli were found in 327 initial fecal samples by plating on LB-ciprofloxacin and CH typing of 1 to 8 single colonies. 328
After the initial fecal sample was analyzed, H30 carriers as well as carriers of some other strains 329 were asked to provide urine samples. These were received on average 152 ± 55.9 days after the 330 initial sample (85% responded). The respondents were then asked to provide follow-up fecal 331 samples, which were received on average 82 ± 41.1 days after the urine sample (84% 332 responded). All fecal and urine samples were tested for ciprofloxacin-resistant E. coli as with 333 initial samples. For this study, we chose 28 individuals who supplied all three samples. In 11 334 participants, H30 was identified in all three samples; in 4 additional participants H30 was 335 isolated in two samples. In 8 participants ciprofloxacin-resistant ST1193 was found in at least 336 two samples. In 5 participants the same ciprofloxacin-susceptible clone was found in at least two 337 samples. The sample types, strains clonal identity, and sampling times for all participants are 338 shown in Supplemental Figure 8 . Average age of participants was 66.7 ± 15.7 years. 339
Preparation of predefined control samples 340
For control experiments, two predefined strains were chosen -H30 (E. coli FESS614.ds6) and 341 clonal group ST101 (E. coli FESS614.ds4). DNA from these strains was extracted and fumC and 342 fimH was amplified by PCR using the following conditions: 3min denaturation (95°C), 35 cycles 343 of annealing (95°C for 45sec, 57°C for 45sec, 72°C for 45sec), 5min extension (72°C), 4°C hold. 344
The primers (10 uM) used were as follows: 5'-TCACAGGTCGCCAGCGCTTC-3' (fumC 345 forward), 5'-GTACGCAGCGAAAAAGATTC3' (fumC reverse), 5'-346 TCAGGGAACCATTCAGGCA-3' (fimH forward), 5-ACAAAGGGCTAACGTGCAG-3' (fimH 347 reverse). Amount of PCR product was measured by Qbit. To create H30-only and ST101-only 348 samples, the corresponding fumC and fimH PCR products were pooled together at a 1:1 ratio. To 349 create mixes, H30 and ST101 amplicons of fumC were mixed together in ST101:H30 ratios of 350 1:1, 1:4, 1:10, 1:100, and 1:1000. The same was performed with fimH amplicons. The fumC and 351 fimH mixes were then pooled together by ratio type to create mixes that had equal concentrations 352 of total fumC and fimH. The DNA mixes were prepared for sequencing using Nextera XT DNA 353 library prep kit using standard protocol. The resulting library was sequenced on the Illumina 354 MiSeq (v3 kit). All mixes, except 1:10, reached coverage of ≥9,000X and were analyzed. 355
Deep sequencing and allele analysis of the fecal and urine samples 356
Each fecal and urine sample was plated on MacConkey agar to reach ~1,000 E. coli single 357 colonies per plate. All colonies were swabbed from the agar and DNA extracted using the 358 Qiagen Blood & Tissue Kit. From this pooled DNA fumC and fimH genes were amplified by 359 PCR by using the same primers and conditions as described above for control samples. 360
Amplicons were then purified and pooled by sample using the Qiagen Gel Extraction kit, then 361 prepared for sequencing using Nextera XT DNA library prep kit using standard protocol except 362 for usage of 52.5ul of RSB in the final magnetic bead cleanup step. The resulting library was 363 sequenced on the Illumina MiSeq (v3 kit). Sequencing data was analyzed using a Python 364 program of our construction, Population-Level Allele Profiler (PLAP), and has been made 365 available for public use on GitHub: github.com/marade/PLAP. The process is described below 366 (see also Suppl. Fig. 9 ). 367
For each sample, adapter sequences were removed using Trim-Galore, and resulting trimmed 368 reads were aligned to a list of all known fumC and fimH alleles using KMA with strict 99.99% 369 identity matching 50, 51 . For each KMA-detected allele per sample, trimmed reads were again 370 18 aligned to the sequence using Minimap2 and SAMtools 52, 53 . Any candidate allele which had at 371 least 1 base supported by <0.8% of reads was removed from consideration. False positives were 372 filtered using a moving 10bp window for each allele as follows. Reads of ≥100bp with 100% 373 identity within the window were counted. Alleles with low initial coverage, unstable coverage 374 (high average deviation from the mean), and high similarity in coverage pattern to an allele with 375 more stable coverage were removed from consideration. If >3 alleles were left for consideration 376 for a gene, 10bp moving window analysis was repeated with ≥200bp reads. If for any interval in 377 this second analysis, >60% of coverage was lost compared to the first moving window coverage, 378 the allele was discarded. Heterogeneity at any positions that remained undescribed by surviving 379 alleles was recorded. Relative abundance of all alleles was determined using the minimum 380 coverage found during first moving window analysis. In samples found by PLAP to be ≥50% 381 made up of <100bp reads (overtagmented samples), allele prevalence was calculated manually 382 by ascertaining base(s) unique to each allele and using the coverage of these base(s) to calculate 383 prevalence. 384
Out of the 28 total sets of fecal and urine samples chosen for this study, at least one sample failed 385 PCR amplification or sequencing library prep in 4 sets and therefore all samples from these sets 386 were dropped. From the remaining 24 sets we were able to sequence fumC and fimH in all three 387 samples. Out of those, 67 (89%) samples -22 first fecal, 24 urine, and 21 second fecalreached 388 ≥9,000X coverage per gene and were included in the analysis. 389
Determining within-sample clonal group breakdown 390
Identity of strains present in a sample was determined by combining fumC and fimH allele 391 numbers and determining the ST type using Enterobase. In uniclonal and unambiguous samples, 392 every allele had one match supported by the equation for maximum acceptable difference 393 19 between same-strain fumC and fimH. Therefore, these alleles formed a CH type based on which 394 ST type was determined. 395
For ambiguous-simple samples, the most prevalent fumC and fimH alleles formed an equation-396 supported CH type. Any alleles that also had a single equation-supported match were assigned to 397 form a CH type. For all other alleles, Enterobase was consulted to determine which allele 398 combinations have been observed. If the CH type(s) produced was between alleles that had 399 different prevalences according to the equation, the "remaining" prevalence was calculated for 400 the allele with the greater prevalence. This allele was then paired with allele(s) for which an 401
Enterobase-logged CH type was not available and/or any novel alleles until the "remaining" 402 prevalence was consumed. If there were any allele(s) that remained after this step, they were 403 paired with the major allele of the opposite gene. 404
For ambiguous-complex samples, the most prevalent fumC and most prevalent fimH allele were 405 assigned to the same CH type. The "remaining" prevalence was calculated for the allele with the 406 greater prevalence and treated as an unmatched allele. From this step, we proceeded as with 407 ambiguous-simple samples. 408
Determining prevalence of clonal groups by culturing 409
Prevalence of ciprofloxacin-resistant clones in each sample was determined by diluting ~1ul of 410 sample with ≥300ul of H2O, plating 40ul of this dilution on MacConkey agar, picking >130 411 single E. coli colonies, patching on Hardy-Chrom UTI agar to verify E. coli identity, then 412 patching colonies on LB-ciprofloxacin. Prevalence of other clonal groups was validated by 413 plating on MacConkey agar and subsequent patching of single colonies onto Hardy-Chrom UTI 414 20 agar to distinguish E. coli. fumC and fimH alleles of these colonies were then determined by 7-415 SNP clonotyping and Sanger sequencing 54 . 416
Statistical and phylogenetic analysis 417
To determine the 99% confidence interval (CI) for the prevalence of ciprofloxacin-resistant 418 strains, the number of resistant colonies was treated as number of successes and the total number 419 of picked colonies was treated as the total. To determine the 99% CI for the prevalence of 420 ciprofloxacin-sensitive strains, the number of colonies of that strain was treated as number of 421 successes and the total number of picked colonies was treated as the total. Confidence intervals 422 were calculated using Stata 55 . All t-tests were run using GraphPad 423 (http://www.graphpad.com/quickcalcs/ConfInterval1.cfm). 424
Phylogenetic trees were constructed using MEGA7 56 . Erroneous base coverage graph was 425 generated using seaborn 57 . Escherichia coli fumC alleles were downloaded from Enterobase 426 MLST allele data. Escherichia coli fimH alleles used are publicly available 58 . Escherichia 427 fergusonii and albertii fumC alleles were downloaded from NCBI. Klebsiella pneumonia and 428
Enterobacter aerogenes alleles of fimH were downloaded from the PATRIC database 429 (www.patricbrc.org). 430 
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